Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

• click to rate

  Posted by Two Blokes Jun 6 - Filed in Stock - 7 views
  
  REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA decision represents a significant catalyst for RGNX shares, offering a compelling pre-approval investment opportunity.